Data Insights

SLS-009 by SELLAS Life Sciences Group for Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma): Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Extranodal Marginal Zone B-Cell...

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Extranodal Marginal Zone B-Cell Lymphoma (Mucosa-Associated Lymphoid Tissue or MALT-Lymphoma)

Data Insights

SLS-009 by SELLAS Life Sciences Group for Relapsed Acute Myeloid Leukemia: Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Relapsed Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Relapsed Acute Myeloid Leukemia

Data Insights

SLS-009 by SELLAS Life Sciences Group for Refractory Acute Myeloid Leukemia: Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Refractory Acute Myeloid Leukemia....

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Refractory Acute Myeloid Leukemia

Data Insights

SLS-009 by SELLAS Life Sciences Group for Refractory Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Refractory Chronic Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Refractory Chronic Lymphocytic Leukemia (CLL)

Data Insights

SLS-009 by SELLAS Life Sciences Group for Relapsed Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Relapsed Chronic Lymphocytic Leukemia...

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Relapsed Chronic Lymphocytic Leukemia (CLL)

Data Insights

SLS-009 by SELLAS Life Sciences Group for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Peripheral T-Cell Lymphomas (PTCL)....

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Peripheral T-Cell Lymphomas (PTCL)

Data Insights

SLS-009 by SELLAS Life Sciences Group for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Diffuse Large B-Cell Lymphoma....

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Diffuse Large B-Cell Lymphoma

Data Insights

SLS-009 by SELLAS Life Sciences Group for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin...

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

SLS-009 by SELLAS Life Sciences Group for Lymphoma: Likelihood of Approval

SLS-009 is under clinical development by SELLAS Life Sciences Group and currently in Phase II for Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SLS-009 in Lymphoma